MX2014013508A - Soluciones proteinicas estabilizadas. - Google Patents

Soluciones proteinicas estabilizadas.

Info

Publication number
MX2014013508A
MX2014013508A MX2014013508A MX2014013508A MX2014013508A MX 2014013508 A MX2014013508 A MX 2014013508A MX 2014013508 A MX2014013508 A MX 2014013508A MX 2014013508 A MX2014013508 A MX 2014013508A MX 2014013508 A MX2014013508 A MX 2014013508A
Authority
MX
Mexico
Prior art keywords
highly concentrated
protein solutions
stabilised protein
sucrose
addition
Prior art date
Application number
MX2014013508A
Other languages
English (en)
Inventor
Ole Elvang Jensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49583182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014013508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014013508A publication Critical patent/MX2014013508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un método para estabilizar soluciones proteínicas sumamente concentradas durante la ultrafiltración por medio de la adición de sacarosa a la solución proteínica sumamente concentrada, en particular, pero no exclusivamente a un método para estabilizar soluciones de anticuerpos sumamente concentradas durante la ultrafiltración por medio de la adición de sacarosa a la solución de anticuerpos sumamente concentrada.
MX2014013508A 2012-05-14 2013-03-15 Soluciones proteinicas estabilizadas. MX2014013508A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167958 2012-05-14
US201261651598P 2012-05-25 2012-05-25
PCT/EP2013/055390 WO2013170977A1 (en) 2012-05-14 2013-03-15 Stabilised protein solutions

Publications (1)

Publication Number Publication Date
MX2014013508A true MX2014013508A (es) 2015-02-10

Family

ID=49583182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013508A MX2014013508A (es) 2012-05-14 2013-03-15 Soluciones proteinicas estabilizadas.

Country Status (10)

Country Link
US (2) US11466051B2 (es)
EP (2) EP2850099B1 (es)
JP (1) JP6681711B2 (es)
CN (1) CN104271600B (es)
AU (1) AU2013262083A1 (es)
BR (1) BR112014028129A2 (es)
CA (1) CA2873647A1 (es)
ES (1) ES2622558T3 (es)
MX (1) MX2014013508A (es)
WO (1) WO2013170977A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274359B1 (en) 2015-03-23 2022-11-02 Alexion Pharmaceuticals, Inc. Virus filtration
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3619565A1 (de) 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
CN1151174C (zh) * 1998-12-21 2004-05-26 蒋盘宏 抗人淋巴细胞球蛋白制备方法
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
EP1610820B2 (en) * 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
DE102004052729A1 (de) 2004-10-30 2006-05-04 Roche Diagnostics Gmbh Immunkomplex-spezifsicher Antikörper zur Reduktion des Nullwerts beim Nachweis von Antigen-spezifisch gebundenen Antikörpern einer bestimmten Immunglobulinklasse in Array-Testformaten
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2677937A1 (en) 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
KR20100120289A (ko) * 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
RU2011101969A (ru) * 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
US20100111853A1 (en) * 2008-10-20 2010-05-06 Abbott Laboratories, Inc. Antibodies that bind to il-12 and methods of purifying the same
AU2009314311B2 (en) 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
CN102821787B (zh) 2010-01-15 2015-07-29 麒麟-安姆根有限公司 抗体制剂和治疗方案
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions

Also Published As

Publication number Publication date
BR112014028129A2 (pt) 2017-06-27
JP2015517506A (ja) 2015-06-22
EP3184542A1 (en) 2017-06-28
CA2873647A1 (en) 2013-11-21
CN104271600B (zh) 2018-09-14
EP2850099A1 (en) 2015-03-25
EP2850099B1 (en) 2017-01-18
CN104271600A (zh) 2015-01-07
US20150086566A1 (en) 2015-03-26
AU2013262083A1 (en) 2014-11-06
WO2013170977A1 (en) 2013-11-21
US20230002443A1 (en) 2023-01-05
ES2622558T3 (es) 2017-07-06
JP6681711B2 (ja) 2020-04-15
US11466051B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
IN2015DN03763A (es)
MY182178A (en) Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
MX2015016535A (es) Metodo de produccion para tagatosa.
WO2013021279A3 (en) Highly galactosylated antibodies
WO2012139134A3 (en) Methods of modulating oncogenic fusion proteins
ZA201508706B (en) Novel cloning, expression & purification method for the preparation of ranibizumab
MX348767B (es) Metodo para preparar mentona a partir de isopulegol.
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
IN2015KN00323A (es)
IT1403684B1 (it) Macchina per la preparazione di bevande mediante infusione.
WO2014017493A9 (ja) ワクチン
MX2015006915A (es) Preparacion de una bebida estable.
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
IN2014MU00455A (es)
EP3268384A4 (en) Process for preparing recombinant insulin using microfiltration
EP2724775A4 (en) PROCESS FOR THE PRODUCTION OF MICRO, SUBMICRO AND NANO CAPSULES BASED ON MILK SERUM PROTEINS
HK1210138A1 (en) Method for producing equilibrium peracetic acid and equilibrium peracetic acid obtainable by the method
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
EA201690245A1 (ru) Оптимизированный способ получения композиции, содержащей изомальтулозу
DK3356550T3 (da) System til forbedrede produktionstitre i fermenteringer
WO2014033158A3 (en) Pcsk9 peptide vaccine
MY186710A (en) Method for producing semi-aromatic copolyamides with a high diamine excess
WO2014118606A3 (en) A novel process for the preparation of silodosin
MX2014013508A (es) Soluciones proteinicas estabilizadas.
EA201200756A1 (ru) Лиофилизат соединения бороновой кислоты